Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

Documenti analoghi

• Risk‐adapted treatment in multiple myeloma: Does more make it merrier?
  di: Saurabh Zanwar, et al.
  Pubblicazione: (2024)
• Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma
  di: Serena Barachini, et al.
  Pubblicazione: (2026)
• A Pilot Study Assessing the Accuracy of AI ChatGPT Responses for AL Amyloidosis
  di: Ludovic Saba, et al.
  Pubblicazione: (2024)